Table 2 Application of CRISPR-Cas9 technology in cancer immunotherapy
From: Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Condition or diseases | Immunotherapy type | Target sites | Identifier | Phase |
|---|---|---|---|---|
T Cell Lymphoma | Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) | Unknown | NCT04502446 | Phase 1 |
Relapsed/Refractory B Cell Non-Hodgkin Lymphoma | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell (CB-010) | Unknown | NCT04637763 | Phase 1 |
Metastatic Non-small Cell Lung Cancer | Autologous lymphocytes | PD-1 | NCT02793856 | Phase 1 |
EBV (Epstein-Barr virus) Positive Advanced-Stage Malignancies | EBV-CTL cells | PD-1 | NCT03044743 | Phase 1/2 |
Metastatic Non-small Cell Lung Cancer | Engineered T cells | PD-1 | NCT02793856 | Phase 1 |
Invasive Bladder Cancer Stage IV | Engineered T cells | PD-1 | NCT02863913 | Phase 1 |
Metastatic Renal Cell Carcinoma | Engineered T cells | PD-1 | NCT02867332 | Phase 1 |
Hormone Refractory Prostate Cancer | Engineered T cells | PD-1 | NCT02867345 | Unknown |
Esophageal Cancer | Engineered T Cells | PD-1 | NCT03081715 | Not Applicable |
Prostate Cancer | Engineered T cells | PD-1 | NCT03525652 | Phase 1/2 |
Advanced Hepatocellular Carcinoma | Engineered T cells | PD-1 | NCT04417764 | Phase 1 |
Solid Tumor, Adult | Mesothelin-directed CAR-T cells | PD-1 | NCT03747965 | Phase 1 |
Tumors of the Central Nervous System | Unknown | NF1 | NCT03332030 | Suspended |
Human Papillomavirus-Related Malignant Neoplasm | Unknown | HPV E6/E7 | NCT03057912 | Phase 1 |
Solid Tumor, Adult | Anti-mesothelin CAR-T cells | Endo-TCR/PD-1 | NCT03545815 | Phase 1 |
Multiple Myeloma; Melanoma; Synovial Sarcoma; Myxoid/Round Cell Liposarcoma | NY-ESO-1 TCR-T | Endo-TCR/PD-1 | NCT03399448 | Phase 1 |
B Cell Leukemia; B Cell Lymphoma | UCART019 | Endo-TCR/B2M | NCT03166878 | Phase 1/2 |
Acute Lymphoblastic Leukemia (ALL) Non Hodgkin Lymphoma (NHL) | UCART019 | Endo-TCR/B2M | NCT03229876 | Not Applicable |
Gastro-Intestinal (GI) Cancer | TIL | CISH | NCT04426669 | Phase 1/2 |
Renal Cell Carcinoma | Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) | CD70 | NCT04438083 | Phase 1 |
Cell Leukemia; U-T-cell Lymphoma | T-CAR-T | CD7/TRAC | NCT04264078 | Early Phase 1 |
High Risk T-cell Malignancies | Non-Edited T Cells (CRIMSON-NE) | CD7 | NCT03690011 | Phase 1 |
B Acute Lymphoblastic Leukemia | Allogenic engineered human T cells | CD25/TRAC | NCT04557436 | Phase 1 |
B Cell Leukemia; B Cell Lymphoma | Universal CAR-T Cells | CD19/CD20/CD22 | NCT03398967 | Phase 1/2 |
B cell ALL | Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) | CD19 | NCT04035434 | Phase 1 |
Relapsed/Refractory B Cell Non-Hodgkin Lymphoma | Allogeneic CRISPR-Cas9-Engineered T Cells (CB-010) | CD19 | NCT04637763 | Phase 1 |
Multiple Myeloma | Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) | BCMA | NCT04244656 | Phase 1 |